Pharming Group N.V.
PHARHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Pharming Group N.V. (PHAR) is listed under Biotechnology. The company carries a $925.2M market cap, placing it firmly in the small-cap category. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Market Cap
$925.2M
Beta
0.12
P/E (TTM)
68.95
P/E (Fwd)
45.12
EPS (TTM)
$0.19
EPS (Fwd)
$0.29
ROE
5.0%
ROA
4.9%
Cash
$170.2M
Total Debt
$116.2M
Free CF
$59.0M
52W Change
16.6%
Annual Financials
Cash vs Debt
Pharming Group N.V. holds $170.2M in cash against $116.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $59.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 5.0% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.9% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $205.6M (2022) to $376.1M (2025), reflecting a 83% increase over the period.
The relatively low beta of 0.12 suggests PHAR is a less volatile holding compared to the broader index. At over 50x earnings, PHAR carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Pharming Group N.V.'s trajectory.